Details for Patent: 9,624,156

Title:	Compounds and methods for delivery of prostacyclin analogs
Abstract:	This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Inventor(s):	Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC), Jeffs; Roger (Chapel Hill, NC)
Assignee:	United Therapeutics Corporation (Silver Spring, MD)
Filing Date:	Oct 28, 2015
Application Number:	14/925,084
Claims:	1. A method of treating pulmonary hypertension comprising administering to a human subject with pulmonary hypertension an effective amount of a compound of formula ##STR00031## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is a substituted or unsubstituted alkyl, R.sup.2 and R.sup.3 are the same or different and are independently selected from the group consisting of H, phosphate, and groups wherein OR.sup.2 and OR.sup.3 form esters of amino acids or proteins; wherein said unsubstituted alkyl is selected from the group consisting of: a) an unbranched alkyl selected from the group consisting of pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and dodecyl; b) a branched alkyl selected from the group consisting of --CH(CH.sub.3)(CH.sub.2CH.sub.3), --CH(CH.sub.2CH.sub.3).sub.2, --C(CH.sub.3).sub.3, --C(CH.sub.2CH.sub.3).sub.3, --CH.sub.2CH(CH.sub.3).sub.2, --CH.sub.2CH(CH.sub.3)(CH.sub.2CH.sub.3), --CH.sub.2CH(CH.sub.2CH.sub.3).sub.2, --CH.sub.2C(CH.sub.3).sub.3, --CH.sub.2C(CH.sub.2CH.sub.3).sub.3, --CH(CH.sub.3)CH(CH.sub.3)(CH.sub.2CH.sub.3), --CH.sub.2CH.sub.2CH(CH.sub.3).sub.2, --CH.sub.2CH.sub.2CH(CH.sub.3)(CH.sub.2CH.sub.3), --CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3).sub.2, --CH.sub.2CH.sub.2C(CH.sub.3).sub.3, --CH.sub.2CH.sub.2C(CH.sub.2CH.sub.3).sub.3, --CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2, --CH(CH.sub.3)CH(CH.sub.3)CH(CH.sub.3).sub.2, and --CH(CH.sub.2CH.sub.3)CH(CH.sub.3)CH(CH.sub.3)(CH.sub.2CH.sub.3); c) a cyclic alkyl selected from the group consisting of cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl; and d) a polycyclic alkyl group, wherein said substituted alkyl is an unsubstituted alkyl as defined above in which one or more bonds to one or more carbon or hydrogen atoms are replaced by a bond to an atom selected from F, Cl, Br, I, O, S, N and Si. 2. The method of claim 1, wherein R.sup.2 and R.sup.3 are each H. 3. The method of claim 1, wherein R.sup.1 is an unbranched alkyl selected from the group consisting of pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, and dodecyl. 4. The method of claim 1, wherein R.sup.1 is a branched alkyl selected from selected from the group consisting of --CH(CH.sub.3)(CH.sub.2CH.sub.3), --CH(CH.sub.2CH.sub.3).sub.2, --C(CH.sub.3).sub.3, --C(CH.sub.2CH.sub.3).sub.3, --CH.sub.2CH(CH.sub.3).sub.2, --CH.sub.2CH(CH.sub.3)(CH.sub.2CH.sub.3), --CH.sub.2CH(CH.sub.2CH.sub.3).sub.2, --CH.sub.2C(CH.sub.3).sub.3, --CH.sub.2C(CH.sub.2CH.sub.3).sub.3, --CH(CH.sub.3)CH(CH.sub.3)(CH.sub.2CH.sub.3), --CH.sub.2CH.sub.2CH(CH.sub.3).sub.2, --CH.sub.2CH.sub.2CH(CH.sub.3)(CH.sub.2CH.sub.3), --CH.sub.2CH.sub.2CH(CH.sub.2CH.sub.3).sub.2, --CH.sub.2CH.sub.2C(CH.sub.3).sub.3, --CH.sub.2CH.sub.2C(CH.sub.2CH.sub.3).sub.3, --CH(CH.sub.3)CH.sub.2CH(CH.sub.3).sub.2, --CH(CH.sub.3)CH(CH.sub.3)CH(CH.sub.3).sub.2, and --CH(CH.sub.2CH.sub.3)CH(CH.sub.3)CH(CH.sub.3)(CH.sub.2CH.sub.3). 5. The method of claim 1, wherein R.sup.1 is a cyclic alkyl selected from the group consisting of cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. 6. The method of claim 1, wherein R.sup.1 is a polycyclic alkyl group. 7. The method of claim 6, wherein the polycyclic alkyl group is adamantyl norbornyl, or bicyclo[2.2.2]octyl. 8. The method of claim 1, wherein R.sup.1 is the substituted alkyl group. 9. The method of claim 8, wherein R.sup.1 is an unsubstituted alkyl, in which one or more bonds to are replaced by a bond to an atom selected from F, Cl, Br, and I. 10. The method of claim 8, wherein R.sup.1 is an unsubstituted alkyl, in which one or more bonds to one or more carbon or hydrogen atoms are replaced by a bond to an oxygen atom. 11. The method of claim 10, wherein said oxygen atom is in a group selected from hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups. 12. The method of claim 8, wherein R.sup.1 is an unsubstituted alkyl, in which one or more bonds to one or more carbon or hydrogen atoms are replaced by a bond to a nitrogen atom. 13. The method of claim 12, wherein said nitrogen atom is in a group selected from amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines. 14. The method of claim 8, wherein R.sup.1 is an unsubstituted alkyl, in which one or more bonds to one or more carbon or hydrogen atoms are replaced by a bond to a sulfur atom. 15. The method of claim 14, wherein the sulfur atom is in a group selected from thiol groups, alkyl and aryl sulfide groups, sulfone groups, sulfonyl groups, and sulfoxide groups. 16. The method of claim 1, wherein said administering comprises administering a pharmaceutical composition comprising a) the compound of claim 1 or the pharmaceutically acceptable salt thereof and b) a pharmaceutically acceptable carrier. 17. The method of claim 1, wherein said administering is performed orally. 18. A method of treating pulmonary hypertension comprising administering to a human subject with pulmonary hypertension an effective amount of a compound of formula: ##STR00032## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is an alkyl, R.sup.2 and R.sup.3 are the same or different and are independently selected from the group consisting of H, phosphate, and groups wherein OR.sup.2 and OR.sup.3 form esters of amino acids or proteins; wherein said alkyl is selected from the group consisting of: a) a straight C.sub.5-C.sub.20 alkyl group; b) a branched C.sub.3-C.sub.20 alkyl group; c) a cyclic C.sub.3-C.sub.20 alkyl group; and d) a polycyclic alkyl group. 19. The method of claim 18, wherein R.sup.1 is a straight C.sub.5-C.sub.20 alkyl. 20. A method of treating pulmonary hypertension comprising administering to a human subject with pulmonary hypertension an effective amount of a compound of formula: ##STR00033## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is a straight C.sub.12-C.sub.20 alkyl, R.sup.2 and R.sup.3 are each H. 21. The method of claim 20, wherein said administering comprises administering a pharmaceutical composition comprising a) the compound of claim 20 or the pharmaceutically acceptable salt thereof and b) a pharmaceutically acceptable carrier. 22. The method of claim 20, wherein said administering is performed orally. 23. A method of treating pulmonary hypertension comprising administering to a human subject with pulmonary hypertension an effective amount of a compound of formula: ##STR00034## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is dodecyl, R.sup.2 and R.sup.3 are each H. 24. The method of claim 23, wherein said administering comprises administering a pharmaceutical composition comprising a) the compound of claim 23 or the pharmaceutically acceptable salt thereof and b) a pharmaceutically acceptable carrier. 25. The method of claim 23, wherein said administering is performed orally. 26. The method of claim 19, wherein said compound is administered in an encapsulated form. 27. The method of claim 26, wherein said compound is administered as a micelle composition. 28. The method of claim 26, wherein said compound is administered as a liposome composition. 29. The method of claim 21, wherein said composition is an encapsulated form. 30. The method of claim 29, wherein said composition is a micelle composition. 31. The method of claim 29, wherein said composition is a liposome composition.